We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
AVTR is backed by a broad portfolio, digital upgrades and improving demand in key markets.
AVTR cited about $100M in new pharma business wins set to begin phasing in from 2026.
AVTR expects positive organic revenue growth in the second half of 2026 as Revival efforts advance.
Avantor, Inc. (AVTR - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by strategic deals and cost transformation progress also looks promising. However, weakness in the VWR Distribution & Services segment remains a cause for concern.
In the year-to-date period, this Zacks Rank #3 (Hold) stock has lost 20.1% compared with 11.2% decline of the industry. The S&P 500 has increased 10.4% in the same time frame.
The renowned provider of mission-critical products and services has a market capitalization of $5.74 billion. The company expects 2.2% earnings growth for the next five years and to witness continued improvements in its business. Avantor’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed twice, delivering an average surprise of 0.7%.
Image Source: Zacks Investment Research
Factors Favoring AVTR’s Growth
Product Portfolio: Avantor offers a broad, integrated portfolio of millions of products and services that enables customized solutions across research, diagnostics and QA/QC workflows, supported by a robust e-commerce platform and the Avantor Business System that drives execution and continuous improvement.
During the first quarter of 2026 earnings call, Avantor highlighted solid progress in its digital transformation efforts, with upgrades to the VWR e-commerce platform and the relaunch of vwr.com driving improved traffic, conversion rates and revenue growth across the United States and Europe. Management noted that stronger commercial execution, a diversified product portfolio and healthier customer engagement are contributing to improving demand trends, particularly in process chemicals, while the Biopharma Production segment delivered a book-to-bill ratio above 1.1x. The company also continues to invest in leadership, sourcing, pricing and digital capabilities to enhance operational efficiency and strengthen its integrated solutions offering across research, bioprocessing and manufacturing markets.
Strategic Deals: Avantor’s third-quarter 2025 earnings call highlighted improving customer engagement and clearer revenue visibility, supported by both innovation-led collaborations and solid commercial execution. Management cited the collaboration with BlueWhale Bio as a step toward advancing next-generation therapy enablement, positioning it primarily as a technology and innovation partnership rather than a near-term revenue driver. More importantly, Avantor pointed to strong commercial momentum, including roughly $100 million in new business wins across two top-15 global pharma customers that will begin phasing in from 2026.
In addition, the company executed a five-year extension with BIO Business Solutions, expanding access to over 10,000 life sciences customers. AVTR secured multiple contract extensions with top-15 global pharma accounts, expected to translate into more than $100 million in share gains over time through a mix of retained and competitive wins, providing a meaningful tailwind to future volumes and market share.
Revival Program and Execution Discipline: Avantor continues to frame the “Avantor Revival” as a company-wide effort to restore growth momentum while strengthening operating execution. First-quarter 2026 results exceeded management’s expectations, and the company reaffirmed full-year 2026 guidance for organic revenue growth of negative 2.5% to negative 0.5% and adjusted earnings per share in the range of 77 cents to 83 cents.
Management attributed the quarter’s outperformance to better execution in Bioscience and Medtech Products, with process chemicals delivering double-digit organic growth and Bioscience and Medtech Products posting a book-to-bill above 1.1x. Leadership actions are also part of the program, with about 25% of the top leadership group refreshed since the Revival launch, and year-to-date headcount is down about 2%. Management’s base case remains that VWR reached a trough in first-quarter 2026 and Bioscience and Medtech Products reach their trough in the second quarter of 2026, positioning Avantor for positive organic revenue growth in the second half of 2026.
A Factor That May Offset AVTR’s Growth
Demand Softness in VWR Distribution & Services: Avantor’s VWR Distribution & Services segment continues to face subdued customer spending across several end markets. In first-quarter 2026, the segment generated $1.15 billion of revenues and declined 5% organically year over year, with management attributing the drop primarily to lower volumes, soft conditions in Europe and adverse winter weather in the United States.
Adjusted operating income in the VWR Distribution & Services segment was $105 million, implying a 9.2% margin, and management cited volume and net price capture as key drivers of the year-over-year margin decline. While management believes the VWR growth rate reached a trough in first-quarter 2026 and expects gradual improvement through the year, near-term performance still depends on a stabilization in academic, government and industrial purchasing behavior.
Estimate Trend
Avantor has been witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its earnings per share has remained stable at 79 cents.
The Zacks Consensus Estimate for second-quarter 2026 revenues is pegged at $1.62 billion, which indicates a 3.5% decline from the year-ago reported number.
Stocks to Consider
Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted earnings per share of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
Key Takeaways
Avantor, Inc. (AVTR - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by strategic deals and cost transformation progress also looks promising. However, weakness in the VWR Distribution & Services segment remains a cause for concern.
In the year-to-date period, this Zacks Rank #3 (Hold) stock has lost 20.1% compared with 11.2% decline of the industry. The S&P 500 has increased 10.4% in the same time frame.
The renowned provider of mission-critical products and services has a market capitalization of $5.74 billion. The company expects 2.2% earnings growth for the next five years and to witness continued improvements in its business. Avantor’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed twice, delivering an average surprise of 0.7%.
Image Source: Zacks Investment Research
Factors Favoring AVTR’s Growth
Product Portfolio: Avantor offers a broad, integrated portfolio of millions of products and services that enables customized solutions across research, diagnostics and QA/QC workflows, supported by a robust e-commerce platform and the Avantor Business System that drives execution and continuous improvement.
During the first quarter of 2026 earnings call, Avantor highlighted solid progress in its digital transformation efforts, with upgrades to the VWR e-commerce platform and the relaunch of vwr.com driving improved traffic, conversion rates and revenue growth across the United States and Europe. Management noted that stronger commercial execution, a diversified product portfolio and healthier customer engagement are contributing to improving demand trends, particularly in process chemicals, while the Biopharma Production segment delivered a book-to-bill ratio above 1.1x. The company also continues to invest in leadership, sourcing, pricing and digital capabilities to enhance operational efficiency and strengthen its integrated solutions offering across research, bioprocessing and manufacturing markets.
Strategic Deals: Avantor’s third-quarter 2025 earnings call highlighted improving customer engagement and clearer revenue visibility, supported by both innovation-led collaborations and solid commercial execution. Management cited the collaboration with BlueWhale Bio as a step toward advancing next-generation therapy enablement, positioning it primarily as a technology and innovation partnership rather than a near-term revenue driver. More importantly, Avantor pointed to strong commercial momentum, including roughly $100 million in new business wins across two top-15 global pharma customers that will begin phasing in from 2026.
In addition, the company executed a five-year extension with BIO Business Solutions, expanding access to over 10,000 life sciences customers. AVTR secured multiple contract extensions with top-15 global pharma accounts, expected to translate into more than $100 million in share gains over time through a mix of retained and competitive wins, providing a meaningful tailwind to future volumes and market share.
Revival Program and Execution Discipline: Avantor continues to frame the “Avantor Revival” as a company-wide effort to restore growth momentum while strengthening operating execution. First-quarter 2026 results exceeded management’s expectations, and the company reaffirmed full-year 2026 guidance for organic revenue growth of negative 2.5% to negative 0.5% and adjusted earnings per share in the range of 77 cents to 83 cents.
Management attributed the quarter’s outperformance to better execution in Bioscience and Medtech Products, with process chemicals delivering double-digit organic growth and Bioscience and Medtech Products posting a book-to-bill above 1.1x. Leadership actions are also part of the program, with about 25% of the top leadership group refreshed since the Revival launch, and year-to-date headcount is down about 2%. Management’s base case remains that VWR reached a trough in first-quarter 2026 and Bioscience and Medtech Products reach their trough in the second quarter of 2026, positioning Avantor for positive organic revenue growth in the second half of 2026.
A Factor That May Offset AVTR’s Growth
Demand Softness in VWR Distribution & Services: Avantor’s VWR Distribution & Services segment continues to face subdued customer spending across several end markets. In first-quarter 2026, the segment generated $1.15 billion of revenues and declined 5% organically year over year, with management attributing the drop primarily to lower volumes, soft conditions in Europe and adverse winter weather in the United States.
Adjusted operating income in the VWR Distribution & Services segment was $105 million, implying a 9.2% margin, and management cited volume and net price capture as key drivers of the year-over-year margin decline. While management believes the VWR growth rate reached a trough in first-quarter 2026 and expects gradual improvement through the year, near-term performance still depends on a stabilization in academic, government and industrial purchasing behavior.
Estimate Trend
Avantor has been witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its earnings per share has remained stable at 79 cents.
The Zacks Consensus Estimate for second-quarter 2026 revenues is pegged at $1.62 billion, which indicates a 3.5% decline from the year-ago reported number.
Stocks to Consider
Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted earnings per share of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.